Elevated Expression of Valosin-Containing Protein (p97) Is Associated with Poor Prognosis of Prostate Cancer

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3007-3012

  Tsujimoto, Yuichi ^a   Tomita, Yasuhiko ^a   Hoshida, Yoshihiko ^a   Kono, Takuro ^b   Oka, Toshitsugu ^b   Yamamoto, Shinji ^a   Nonomura, Norio ^a   Okuyama, Akihiko ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIANDROGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONSERVATIVE TREATMENT; CORRELATION FUNCTION; DIGITAL RADIOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 2442536929     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0191     Document Type: Article

References (29)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publ. Lyon, France: IARC; 2002.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA - Cancer J Clin 1996;46:5-27.
3. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
4. Lepor H, Walsh PC. The role of radical prostatectomy in the management of stage B adenocarcinoma of the prostate. Prog Clin Biol Res 1987;243B:343-56.
5. Arai Y. Radical prostatectomy: time trends, morbidity and quality of life. Int J Urol 2001;8:S15-8.
6. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
7. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
8. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222-72.
9. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J Am Med Assoc 1997;277:1445-51.
10. Asai T, Tomita Y, Nakatsuka S, et al. VCP (p97) regulates NFκB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93:296-304.
11. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001;3:740-4.
12. Dou QP, Smith DM, Daniel KG, Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog Cell Cycle Res 2003;5:441-6.
13. Yamamoto S, Tomita Y, Nakamori S, et al. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 2003; 21:447-52.
14. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol 2003;21:2537-44.
15. Schroder FH, Hermanek P, Denis L, et al. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
16. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991;88:7276-80.
17. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
18. Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 187-220.
20. Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst (Bethesda) 1988;80:683-7.
21. McNeal JE. Origin and development of carcinoma in the prostate. Cancer (Phila) 1969;23:24-34.
22. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer (Phila) 1997;80:1835-44.
23. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst (Bethesda) 1999;91:1017-24.
24. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 1996;47:366-9.
25. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results. Int J Cancer 1994;58:211-6.
26. Suzuki H, Akakura K, Ueda T, et al. Clinical characteristics of prostate cancer in elderly Japanese patients 80 years of age or older. Eur Urol 2002;41:172-7.
27. Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer. Eur Urol 1997;32:404-9.
28. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-9.
29. Muller JM, Meyer HH, Ruhrberg C, et al. The mouse p97 (CDC48) gene. Genomic structure, definition of transcriptional regulatory sequences, gene expression, and characterization of a pseudogene. J Biol Chem 1999;274:10154-62.